Literature DB >> 32643105

3D navigation system allows remarkable reduction in fluoroscopy use during cavo-tricuspid isthmus ablation.

Benoit Robaye1, Olivier Deceuninck2,3, Dominique Blommaert2, Véronique Godeaux2, Fabien Dormal2, Benoit Collet2, Elisabeth Ballant2, Florence Huys2, Antoine Guedes2, Olivier Xhaët2.   

Abstract

PURPOSE: Typical atrial flutter (AFL) is one of the most common supraventricular arrhythmias. Its treatment mainly relies on cavo-tricuspid isthmus (CTI) ablation, which can be performed either using conventional fluoroscopy, still mainly used, or 3D navigation system to track the position of the catheter. The aim of this study is to show that the use of a 3D navigation system allows a dramatic reduction of fluoroscopy use during CTI ablation, without any loss of efficacy, time, or safety.
METHODS: In this single-center study, we retrospectively compared 134 cases of CTI ablation performed for typical AFL without a 3D navigation system with 95 cases of CTI ablation performed with such a 3D system. We compared the rates of procedural success (defined as obtaining a bidirectional electrical conduction block), freedom from AFL recurrence at 1-year follow-up, procedural time and safety, and fluoroscopy use.
RESULTS: Compared to conventional fluoroscopy, the use of a 3D navigation system significantly decreased the duration of fluoroscopy use (2 min 13 s ± 2 min 16 s versus 14 min 41 s ± 10 min 39 s, p < 0.0001) and dose-area products (1567.9 ± 1329.5 mGy cm2 versus 8263.3 ± 8636.6 mGy cm2, p < 0.0001). Procedure success rates, duration, and safety were not different between groups.
CONCLUSIONS: The use of 3D navigation during CTI ablation substantially reduces fluoroscopy use duration, without reducing the success rates and safety or prolonging the procedure duration, as compared to conventional fluoroscopy. We therefore suggest the generalization of this navigation system.
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  3D; Ablation; Atrial flutter; Carto; Cavo-tricuspid isthmus; Fluoroscopy; Flutter ablation; Supraventricular tachycardia; Typical flutter

Year:  2020        PMID: 32643105     DOI: 10.1007/s10840-020-00818-7

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  4 in total

1.  Cavotricuspid isthmus ablation using ablation index in typical right atrial flutter.

Authors:  Tao Zhang; Yunlong Wang; Zhihong Han; Hua Zhao; Zhuo Liang; Ye Wang; Yongquan Wu; Xuejun Ren
Journal:  J Cardiovasc Electrophysiol       Date:  2019-09-25

2.  2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).

Authors:  Josep Brugada; Demosthenes G Katritsis; Elena Arbelo; Fernando Arribas; Jeroen J Bax; Carina Blomström-Lundqvist; Hugh Calkins; Domenico Corrado; Spyridon G Deftereos; Gerhard-Paul Diller; Juan J Gomez-Doblas; Bulent Gorenek; Andrew Grace; Siew Yen Ho; Juan-Carlos Kaski; Karl-Heinz Kuck; Pier David Lambiase; Frederic Sacher; Georgia Sarquella-Brugada; Piotr Suwalski; Antonio Zaza
Journal:  Eur Heart J       Date:  2020-02-01       Impact factor: 29.983

3.  Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry.

Authors:  Johannes Brachmann; Thorsten Lewalter; Karl-Heinz Kuck; Dietrich Andresen; Stephan Willems; Stefan G Spitzer; Florian Straube; Burghard Schumacher; Lars Eckardt; Dejan Danilovic; Dierk Thomas; Matthias Hochadel; Jochen Senges
Journal:  Eur Heart J       Date:  2017-05-01       Impact factor: 29.983

4.  A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes.

Authors:  Fredrik Holmqvist; Milos Kesek; Anders Englund; Carina Blomström-Lundqvist; Lars O Karlsson; Göran Kennebäck; Dritan Poçi; Romeo Samo-Ayou; Runa Sigurjónsdóttir; Michael Ringborn; Csaba Herczku; Jonas Carlson; Espen Fengsrud; Fariborz Tabrizi; Niklas Höglund; Stefan Lönnerholm; Ole Kongstad; Anders Jönsson; Per Insulander
Journal:  Eur Heart J       Date:  2019-03-07       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.